RxDoctor Payments Data

Ivan Anderson, MD

Cardiovascular Disease · Auburn, CANPI 1891960076

Payments from drug & device makers

$2,140in general payments, 2019–2025

Across 9 payments — averaging $237.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$1K
  • Atricure, Inc.$179
  • Medtronic$148
  • Abbott$123
  • Alnylam Pharmaceuticals Inc.$120
  • Lantheus Medical Imaging, Inc.$117
  • plus $47 from 2 others

What the payments were for

  • Food & beverage$733100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,140 in reported general payments places this provider in the 45th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$458,492
Medicare patients
1,464
Services billed
5,024

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan690$901,792
EliquisApixaban564$771,614
JardianceEmpagliflozin441$479,261
XareltoRivaroxaban176$235,046
Repatha SureclickEvolocumab115$115,507
MultaqDronedarone Hcl64$109,598
FarxigaDapagliflozin Propanediol94$108,324
Praluent PenAlirocumab68$68,657
Atorvastatin Calcium919$9,066
Ezetimibe382$8,575
Metoprolol Succinate583$7,754
Rosuvastatin Calcium314$6,462
Dabigatran EtexilateDabigatran Etexilate Mesylate23$5,930
Losartan Potassium405$5,013
Spironolactone445$4,721

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$1,406$479,261441 claims
Johnson & JohnsonXarelto$16$235,046176 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Auburn

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →